Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biohaven Ltd.BHVN · Entity 4379 | Director | April 28, 2026 | May 01, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director | October 03, 2022 | October 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biohaven Ltd.
Report date April 28, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28 | Direct | 68,693 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 5,070 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2026 Filed May 1, 2026 00:08 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 68,693 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001926476-26-000002 · wk-form4_1777594081.xml · derivative · entry 1 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,693 Underlying: Common Shares · 68,693 shares Expires 2036-04-28 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| May 05, 2025 Filed May 7, 2025 21:16 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 31,716 | $0.00 Strike: $22.62 | $0.00 |
DisclosureSEC source: 0001935979-25-000048 · wk-form4_1746652555.xml · derivative · entry 1 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716 Underlying: Common Shares · 31,716 shares Expires 2035-05-05 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2026 or (b) the date of the 2026 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:33 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003751 · primarydocument.xml · derivative · entry 1 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 23:25 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-23-008590 · primarydocument.xml · derivative · entry 3 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,000 Underlying: Common Shares · 11,000 shares Expires 2032-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 23:25 UTC | Biohaven Ltd. BHVN · Entity 4379 | SaleCommon Shares | 11,000 | $41.79 | $459,662.50 |
DisclosureSEC source: 0001562180-23-008590 · primarydocument.xml · nonDerivative · entry 2 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,535 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.74 - $41.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 23:25 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-008590 · primarydocument.xml · nonDerivative · entry 1 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:51 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 52,906 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001562180-23-003943 · primarydocument.xml · derivative · entry 1 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,906 Underlying: Common Shares · 52,906 shares Expires 2033-05-02 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 2, 2024 or (b) the date of the 2024 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:25 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerRestricted Share Unit Award · Derivative | 5,070 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-006954 · primarydocument.xml · derivative · entry 1 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,070 shares Expires not disclosed F1 · derivative.exercise_price: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · derivative.exercise_price: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F2 · shares: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F2 · price: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F2 · derivative.exercise_date: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F2 · derivative.expiration_date: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:41 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007084 · primarydocument.xml · derivative · entry 2 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-10-04 F3 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:41 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 2,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007084 · primarydocument.xml · nonDerivative · entry 1 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,535 F1 · shares: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of common shares ("Common Shares") of the Issuer (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. (Cont'd in FN2) F2 · shares: (Cont'd from FN1) As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and will subsequently be settled in Common Shares. Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantRestricted Share Unit Award · Derivative | 5,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004013 · primarydocument.xml · derivative · entry 1 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,070 Underlying: Common Shares · 5,070 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the issuer. F2 · derivative.exercise_date: The reporting person was granted 5,070 restricted share units on May 11, 2022, vesting in four equal installments on May 11, 2022, 2023, 2024 and 2025 subject to the reporting person's continued service with the issuer at each vesting date. F3 · derivative.expiration_date: Not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.